## SEC Form 4

Instruction 1(b)

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WYSZOMIERSKI JACK L					er Name and Tick			Symbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
					2 Dat	e of Earliest Transa	-	lonth/	Day/Year)		Director	10% C				
(Last)	(F	irst)	(Middle)			6/2024		ionun/	Day/fear)		Officer (give title below)	below)	specify			
C/O EXELIXIS, INC.				4. If Ai	mendment, Date of	Origina	I Filed	(Month/Day/		6. Individual or Joint/Group Filing (Check Applicable						
1851 HARBOR BAY PARKWAY										Line)	Form filed by One	Departing Dara				
(Street)											X	Form filed by Mor				
ALAME	EDA C	A	94502									Person				
					<ul> <li>Rule 10b5-1(c) Transaction Indication</li> </ul>											
(City)	(S	state)	(Zip)		$\overline{X}$ Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See In								plan that is intende	ed to		
		Ta	ble I - No	on-Deriv	ative S	Securities Acc	quired	, Dis	posed of,	or Ber	neficially	Owned				
Date			2. Transa Date (Month/D		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code V		Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)					
Common Stock 05/									11.606							
Common	Stock			05/13/	2024		М		11,686	A	\$19.57	349,871 <sup>(1)</sup>	D			
Common Common				05/13/ 05/13/			M S <sup>(2)</sup>		11,686	A D	\$19.57 \$21.37 <sup>(3)</sup>	349,871 <sup>(1)</sup> 338,948 <sup>(1)</sup>	D D			
			Table II	05/13/ - Deriva	2024 tive Se	ecurities Acqualls, warrants,	s <sup>(2)</sup>		10,923 osed of, c	D or Bene	\$21.37 <sup>(3)</sup>	338,948 <sup>(1)</sup>				

Security (Instr. 3)		2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
	Option (right to buy)	\$19.57	05/13/2024		М			11,686	05/25/2017 <sup>(4)</sup>	05/24/2024	Common Stock	11,686	\$0	0	D		

## Explanation of Responses:

1. Includes 20,718 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 12, 2024.

3. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$21.30 to \$21.44. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

4. The option, representing the right to purchase a total of 11,686 shares of Exelixis, Inc. common stock, became fully exercisable on May 25, 2017.

## **Remarks:**

/s/ Nina Ayer, Attorney in Fact 05/15/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.